Cargando…

O02 Nitrofurantoin: what is the evidence for current guidance?

In this abstract, we review current approaches to the management of uncomplicated urinary tract infection (UTI) and begin to explore alternative approaches to antibiotic prescribing. We review clinical guidelines on the use of nitrofurantoin internationally to capture the level of variation in evide...

Descripción completa

Detalles Bibliográficos
Autores principales: Kashouris, Eleanor, Joseph, Amelia, Lewis, Tom
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10395443/
http://dx.doi.org/10.1093/jacamr/dlad077.002
_version_ 1785083577813172224
author Kashouris, Eleanor
Joseph, Amelia
Lewis, Tom
author_facet Kashouris, Eleanor
Joseph, Amelia
Lewis, Tom
author_sort Kashouris, Eleanor
collection PubMed
description In this abstract, we review current approaches to the management of uncomplicated urinary tract infection (UTI) and begin to explore alternative approaches to antibiotic prescribing. We review clinical guidelines on the use of nitrofurantoin internationally to capture the level of variation in evidence-based guidance. We find that the evidence base has been interpreted in very different ways. UK guidelines from NICE and the Scottish Intercollegiate Guidelines Network (SIGN) are unusual in promoting short (3 day) courses of nitrofurantoin. We find little direct evidence to support this, and that this guidance has been extrapolated from studies based on other agents. ‘Short’ courses of antibiotics aim to provide optimum balance between providing effective treatment whilst reducing selective pressure driving resistance amongst colonizing microbial flora. Three days of nitrofurantoin may indeed be a useful intervention in a large group of patients. Longer courses of nitrofurantoin still demonstrate considerable rates of treatment failure. The concept of a course length in itself is limited. The variation between recommendations internationally reflects both the uncertain foundations upon which evidence-based guidelines are written, and the limits of what can be safely concluded from evidence. We join others in pointing out there may be ways of customizing duration of therapy to the patient’s response in primary care settings. There is a need for a more patient-focused approach to uncomplicated UTI, including better safety-netting and (currently lacking) guidance on best practice in the common clinical scenario of treatment failure.
format Online
Article
Text
id pubmed-10395443
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-103954432023-08-03 O02 Nitrofurantoin: what is the evidence for current guidance? Kashouris, Eleanor Joseph, Amelia Lewis, Tom JAC Antimicrob Resist Abstracts In this abstract, we review current approaches to the management of uncomplicated urinary tract infection (UTI) and begin to explore alternative approaches to antibiotic prescribing. We review clinical guidelines on the use of nitrofurantoin internationally to capture the level of variation in evidence-based guidance. We find that the evidence base has been interpreted in very different ways. UK guidelines from NICE and the Scottish Intercollegiate Guidelines Network (SIGN) are unusual in promoting short (3 day) courses of nitrofurantoin. We find little direct evidence to support this, and that this guidance has been extrapolated from studies based on other agents. ‘Short’ courses of antibiotics aim to provide optimum balance between providing effective treatment whilst reducing selective pressure driving resistance amongst colonizing microbial flora. Three days of nitrofurantoin may indeed be a useful intervention in a large group of patients. Longer courses of nitrofurantoin still demonstrate considerable rates of treatment failure. The concept of a course length in itself is limited. The variation between recommendations internationally reflects both the uncertain foundations upon which evidence-based guidelines are written, and the limits of what can be safely concluded from evidence. We join others in pointing out there may be ways of customizing duration of therapy to the patient’s response in primary care settings. There is a need for a more patient-focused approach to uncomplicated UTI, including better safety-netting and (currently lacking) guidance on best practice in the common clinical scenario of treatment failure. Oxford University Press 2023-08-02 /pmc/articles/PMC10395443/ http://dx.doi.org/10.1093/jacamr/dlad077.002 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstracts
Kashouris, Eleanor
Joseph, Amelia
Lewis, Tom
O02 Nitrofurantoin: what is the evidence for current guidance?
title O02 Nitrofurantoin: what is the evidence for current guidance?
title_full O02 Nitrofurantoin: what is the evidence for current guidance?
title_fullStr O02 Nitrofurantoin: what is the evidence for current guidance?
title_full_unstemmed O02 Nitrofurantoin: what is the evidence for current guidance?
title_short O02 Nitrofurantoin: what is the evidence for current guidance?
title_sort o02 nitrofurantoin: what is the evidence for current guidance?
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10395443/
http://dx.doi.org/10.1093/jacamr/dlad077.002
work_keys_str_mv AT kashouriseleanor o02nitrofurantoinwhatistheevidenceforcurrentguidance
AT josephamelia o02nitrofurantoinwhatistheevidenceforcurrentguidance
AT lewistom o02nitrofurantoinwhatistheevidenceforcurrentguidance